BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26559880)

  • 1. Development of Group A streptococcal vaccines: an unmet global health need.
    Sheel M; Moreland NJ; Fraser JD; Carapetis J
    Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF; Pandey M; Batzloff MR; Tyrrell GJ
    Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop.
    Moreland NJ; Waddington CS; Williamson DA; Sriskandan S; Smeesters PR; Proft T; Steer AC; Walker MJ; Baker EN; Baker MG; Lennon D; Dunbar R; Carapetis J; Fraser JD
    Vaccine; 2014 Jun; 32(30):3713-20. PubMed ID: 24837510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.
    Williamson DA; Smeesters PR; Steer AC; Morgan J; Davies M; Carter P; Upton A; Tong SY; Fraser J; Moreland NJ
    BMC Infect Dis; 2016 Oct; 16(1):561. PubMed ID: 27733129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development strategy for a candidate group A streptococcal vaccine.
    Schödel F; Moreland NJ; Wittes JT; Mulholland K; Frazer I; Steer AC; Fraser JD; Carapetis J
    Vaccine; 2017 Apr; 35(16):2007-2014. PubMed ID: 28318768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of group A streptococcal vaccine development.
    Dale JB
    Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine development for group A streptococcus infections and associated disease.
    Batzloff MR; Sriprakash KS; Good MF
    Curr Drug Targets; 2004 Jan; 5(1):57-69. PubMed ID: 14738218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies in the development of vaccines to prevent infections with group A streptococcus.
    Good MF; Batzloff MR; Pandey M
    Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Experimental Group A
    Rivera-Hernandez T; Carnathan DG; Jones S; Cork AJ; Davies MR; Moyle PM; Toth I; Batzloff MR; McCarthy J; Nizet V; Goldblatt D; Silvestri G; Walker MJ
    mBio; 2019 Apr; 10(2):. PubMed ID: 31040243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biology of Group A
    Brahmadathan NK
    Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
    J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
    Nakakana U; Serry-Bangura A; Edem BE; Tessitore P; Di Cesare L; Moriel DG; Podda A; De Ryck IS; Arora AK
    Drugs R D; 2024 Mar; 24(1):1-12. PubMed ID: 38494581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein adhesins as vaccine antigens for Group A Streptococcus.
    Raynes JM; Young PG; Proft T; Williamson DA; Baker EN; Moreland NJ
    Pathog Dis; 2018 Mar; 76(2):. PubMed ID: 29718270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
    Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
    Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group A streptococcal vaccines: facts versus fantasy.
    Steer AC; Batzloff MR; Mulholland K; Carapetis JR
    Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on group A streptococcal vaccine development.
    Dale JB; Walker MJ
    Curr Opin Infect Dis; 2020 Jun; 33(3):244-250. PubMed ID: 32304470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.
    Pandey M; Sekuloski S; Batzloff MR
    Immunol Cell Biol; 2009 Jul; 87(5):391-9. PubMed ID: 19417770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 20. Group A streptococcal infections in children.
    Steer AC; Danchin MH; Carapetis JR
    J Paediatr Child Health; 2007 Apr; 43(4):203-13. PubMed ID: 17444820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.